dpp 4 inhibitor with glp 1 dpp-4_inhibitors [TUSOM Mechanisms of dipeptidyl peptidase‐4 (DPP‐4)

Altimmune just made a big move in the world of GLP-1 research, but this time, its not about obesity.The company announced yesterday that it has officially begun enrolling participants in a Phase 2 trial of pemvidutide, its GLP-1 and glucagon dual receptor agonist, to evaluate the drug in people with Alcohol Use Disorder, or AUD

Harness the power of nature for comprehensive metabolic support

A succinct review Science Magazine | 33 comments on LinkedIn

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with weight-loss drugmaker Novo Nordisk abruptly ended.

OR2=0.21 [95% CI 0.050.92], P2=3.89102)

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications that have gained significant attention in recent years for their ability to manage blood sugar levels and promote weight loss